Health IT startup CellepathicRx will provide the mobile platform for Adheris’ patient medication adherence program.
The deal is worth noting because it’s significant for a young company like Cleveland-based CellepathicRx to receive validation of its technology from a more established company like Adheris, which works with pharmacies to help patients better follow medication instructions.
Massachusetts-based Adheris’ pharmacy network includes more than 20,000 pharmacies, which accounts for approximately 45 percent of all retail prescriptions in the U.S., according to a statement.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The deal will allow Adheris to expand its medication adherence offerings to mobile users, a demographic expected to grow dramatically in the coming years.
“The use of mobile applications and texting is skyrocketing, so this relationship gives our pharmacy partners the opportunity to offer their patients choices regarding their healthcare — whether it be receiving reminders, medication education and/or copay assistance via email, mobile device or traditional mail,” said Jim Rotsart, an executive vice president with Adheris.
CellepathicRx is affiliated with Access Mobility, a company started in 2008 to take advantage of consumers’ migration to the mobile web. The 11-employee company has raised $1.8 million in angel funding so far and is looking to land a subsequent investment round of up to $2 million, Access CEO Greg Muffler said in March.
